

1Q Fiscal 2025 Webcast



February 20, 2025







Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as "may," "will," "should," "could," "expects," "anticipates," "believes," "projects," "forecasts," "outlook," "guidance," "continue," "target," or the negative of these terms or comparable terminology. These statements reflect management's current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions, including the Company's ability to successfully integrate acquisitions; the Company's ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements, including new or increased tariffs or trade restrictions; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, conflicts or wars between sovereign nations, acts of terror, natural disasters and pandemics, including the coronavirus (COVID-19) pandemic and the other factors discussed in Item 1A (Risk Factors) in the Company's most recently filed Annual Report on Form 10-K and in its Forms 10-Q filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement in this presentation.

Agenda



1Q 2025 Webcast – February 20, 2025

- 1st Quarter Highlights
- Sales Performance and Earnings Review
- Balance Sheet and Cash Flow

- Enterprise Performance
- 2Q 2025 Guidance
- Q&A



Sundaram Nagarajan
President &
Chief Executive Officer



Dan Hopgood
Executive Vice President &
Chief Financial Officer



Lara Mahoney
Vice President,
Investor Relations

1Q 25 Highlights Managed earnings and cash flow in challenging demand environment

- Sales of \$615M at the low end of guidance range, reflecting market uncertainty
- Order entry and backlog improving across all segments
- Operational excellence driving strong profit performance despite weaker sales environment
- Atrion acquisition continues to perform above valuation model expectations
- Strong cash flow performance and balanced capital deployment



Total Company – 1Q 2025




Sales

- Reported sales of \$615M, a decrease of 3%, at the low end of prior guidance range
- 8% growth from the Atrion acquisition; unfavorable currency impact of 2%
- 9% organic decrease driven by weakness in polymer processing, industrial coatings, electronics dispense, and select medical product lines

EBITDA*

- EBITDA was \$188 million, down 4% on lower sales volume
- Strong EBITDA margin of 31% in line with prior year

1Q 2025 Sales Bridge**



	1Q 2024	1Q 2025	Δ
Sales	\$633.2	\$615.4	-3%
Operating Profit*	\$163.0	\$151.1	-7%
EBITDA*	\$196.5	\$188.1	-4%
EPS GAAP	\$1.90	\$1.65	-14%
EPS Adjusted*	\$2.21	\$2.06	-7%

^{*}Non-GAAP numbers - See appendix for reconciliation. In millions except for per share data.

Industrial Precision Solutions – 1Q 2025



Sales

- Sales of \$300 million, a decrease of 11%
- Organic decrease of 8% driven by weaker systems demand in polymer processing and industrial coatings product lines, partially offset by growth in nonwovens and packaging product lines


EBITDA*

- EBITDA was \$113 million, or 38% of sales, with decremental margins of 34%
- EBITDA margin improved on lower net sales due to higher mix of parts and consumables

1Q 2025 IPS Sales Bridge**



EBITDA and Margin



⁶

^{*}Non-GAAP numbers – See appendix for reconciliation.

^{**}Amounts may not add due to rounding.

Medical and Fluid Solutions – 1Q 2025




Sales


- Sales of \$194 million, an increase of 21%
- 33% growth from strong Atrion acquisition performance
- 11% organic decrease driven by decline in medical interventional solutions due to customer destocking trends and MFS long-term strategic program rationalization

EBITDA*

 EBITDA was \$64 million, or 33% of sales, despite the full quarter inclusion of Atrion and lower organic sales volumes



EBITDA and Margin



⁷

^{*}Non-GAAP numbers – See appendix for reconciliation.

^{**}Amounts may not add due to rounding.

Advanced Technology Solutions – 1Q 2025




Sales

- Sales were \$121 million, an 11% decrease
- 10% organic decline driven by timing of electronics dispense and x-ray systems deliveries, partially offset by double-digit growth in optical sensors and measurement and control product lines
- Orders accelerating at the end of the quarter across all product lines well above prior year

EBITDA*

- EBITDA was flat year over year at \$23 million, or 19% of sales despite lower sales
- EBITDA margin 200 bps above prior year due to strong cost management and manufacturing improvements

1Q 2025 ATS Sales Bridge**



EBITDA and Margin



^{*}Non-GAAP numbers – See appendix for reconciliation.

^{**}Amounts may not add due to rounding.


Balance Sheet and Cash Flow



Balanced Capital Deployment Returning Value to Shareholders


Net Debt

- Cash totaled \$130 million
- 2.4x net debt leverage ratio based on trailing 12-month EBITDA, a reduction from prior quarter



Free Cash Flow*

- Cash flow of \$138 million, which is a conversion rate of 146% of net income, deployed toward:
 - Share repurchases of \$60M
 - Dividend payments of \$45M
 - Capital investments of \$21M



^{*}Non-GAAP number – See appendix for reconciliation.

Strategically positioned for growth







- Strong technology portfolio, including successful new product launch
- Integration proceeding well
- Exceeding valuation model expectations



- three industry awards
- QuadraPro X-Ray System recognized by Productronica
- ARAG Orion Pro wins EIMA technical innovation award
- Supplier awards from TSMC and Jabil

- Differentiated products
- Customer intimate sales model
- Diversified niche of end markets
- Owner Mindset
- High quality growth compounder in all environments

Steadfast competitive advantages


2Q Fiscal 2025 Guidance



Steady performance moving into 2Q

- Historical seasonality and order entry trends support moderate increases in sales and earnings sequentially
- Backlog grew by ~\$85 million or 15% in the first quarter, ending at approximately \$670 million
- Order entry progressively improved throughout the quarter across all segments

Maintaining full-year guidance ranges, with sales expected to be toward the low end



Questions?





Net Income to Adjusted EBITDA (Dollars in thousands)

NORDSON CORPORATION

RECONCILIATION OF NON-GAAP MEASURES - NET INCOME TO EBITDA (Unaudited)
(Dollars in thousands)

	Three M	Three Months Ended		
	January 31, 2025	January 31, 2024		
Net income	\$ 94,65	2 \$ 109,572		
Income taxes	22,20	3 29,127		
Interest expense - net	25,61	8 20,398		
Other income (expense) - net	(1,52	6) 338		
Depreciation and amortization	37,03	0 33,544		
Inventory step-up amortization (1)	3,13	5 2,944		
Severance and other	5,96	1 —		
Acquisition-related costs (1)	1,03	0 597		
EBITDA (non-GAAP) (2)	\$ 188,10	3 \$ 196,520		

⁽¹⁾ Represents fees, severance and non-cash inventory charges associated with acquisitions.

⁽²⁾ EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as severance, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization.



Adjusted Operating Profit and EBITDA (Dollars in thousands)

NORDSON CORPORATION

RECONCILIATION OF NON-GAAP MEASURES - EBITDA (Unaudited)
(Dollars in thousands)

	Three Months Ended			
	January 31, 2025	January 31, 2024		
SALES BY SEGMENT				
Industrial Precision Solutions	\$ 300,448	\$ 337,742		
Medical and Fluid Solutions	193,609	159,526		
Advanced Technology Solutions	121,363	135,925		
Total sales	\$ 615,420	\$ 633,193		
OPERATING PROFIT				
Industrial Precision Solutions	\$ 95,712	\$ 109,098		
Medical and Fluid Solutions	40,936	46,100		
Advanced Technology Solutions	18,123	18,304		
Corporate	(13,824)	(14,067)		
Total operating profit	\$ 140,947	\$ 159,435		
OPERATING PROFIT ADJUSTMENTS (1)				
Industrial Precision Solutions	\$ 4,611	\$ 3,541		
Medical and Fluid Solutions	5,255	_		
Corporate	260	_		
Total adjustments	\$ 10,126	\$ 3,541		
DEPRECIATION & AMORTIZATION				
Industrial Precision Solutions	\$ 12.453	\$ 12.920		
Medical and Fluid Solutions	18.141	13.705		
Advanced Technology Solutions	4.648	4.901		
Corporate	1.788	2.018		
Total depreciation & amortization	\$ 37,030	\$ 33,544		
EBITDA (NON-GAAP) (2)				
Industrial Precision Solutions	\$ 112.776 38%	\$ 125.559 37%		
Medical and Fluid Solutions	64.332 33%	,		
Advanced Technology Solutions	22.771 19%	,		
Advanced Technology Solutions Corporate	(11.776)	(12,049)		
Total EBITDA		\$ 196,520 31%		
TOTAL EDITOR	\$ 188,103 31%	\$ 190,520 31%		

⁽¹⁾ Represents severance as well as fees and non-cash inventory charges associated with acquisitions.

⁽²⁾ EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as severance, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization.



Profitability (Dollars in thousands)

NORDSON CORPORATION

RECONCILIATION OF NON-GAAP MEASURES - ADJUSTED NET INCOME AND EARNINGS PER SHARE
(Unaudited)
(Dollars in thousands)

		Three Months Ended			
	J	January 31, 2025		January 31, 2024	
GAAP AS REPORTED					
Operating profit	\$	140,947	\$	159,435	
Other / interest expense - net		(24,092)		(20,736)	
Net income		94,652		109,572	
Diluted earnings per share	\$	1.65	\$	1.90	
Shares outstanding - diluted		57,486		57,555	
OPERATING PROFIT ADJUSTMENTS					
Inventory step-up amortization	S	3,135	\$	2,944	
Acquisition costs		1,030		597	
Severance and other		5,961		_	
ACQUISITION AMORTIZATION OF INTANGIBLES	S	19,311	\$	19,387	
INTEREST					
Total adjustments	\$	29,437	\$	22,928	
	_	20,107	Ť	22,720	
Adjustments net of tax	\$	23,844	\$	18,113	
EPS effect of adjustments and other discrete tax items	\$	0.41	\$	0.31	
NON-GAAP MEASURES-ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE					
Adjusted Net income (1)	s	118,496	\$	127,685	
Adjusted Diluted earnings per share (2)	S	2.06	S	2.21	

⁽¹⁾ Adjusted net income is a non-GAAP measure defined as net income plus tax effected adjustments and other discrete tax items

⁽²⁾ Adjusted earnings per share is a non-GAAP measure defined as GAAP EPS adjusted for tax effected adjustments and other discrete tax items.



Operating Cash Flow to Free Cash Flow

NORDSON CORPORATION

RECONCILIATION OF NON-GAAP MEASURES - OPERATING CASH FLOW TO FREE CASH FLOW (Unaudited)
(Dollars in thousands)

	Year to Date
	January 31, 2025
Net cash provided by operating activities	\$ 159,122
Additions to property, plant and equipment	(21,399)
Free Cash Flow - Year to Date (1)	137,723
Net Income - Year to Date	\$ 94,652
Free Cash Flow Conversion (2)	146 %
	Year to Date
	January 31, 2024
Net cash provided by operating activities	\$ 172,356
Additions to property, plant and equipment	(7,530)
Free Cash Flow - Year to Date (1)	164,826

⁽¹⁾ Free Cash Flow - Year to Date is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Net cash provided by operating activities minus Additions to property, plant and equipment.

⁽²⁾ Free Cash Flow Conversion - Year to Date is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Free Cash Flow - Year to Date divided by Net Income - Year to Date.